This may be a relief. However, there is also the frustrating fact that even if a woman has a negative genetic test, she is still at higher risk for breast cancer than the general population due to the risk factor of having multiple family members with breast cancer. Another possibility with...
Cost EffectivenessGenetic TestingBreast CancerBackground: Targeted genetic testing is a tool to identify women at increased risk of gynaecological cancer.Koldehoff, AndreasUniv Hosp Cologne AoRDanner, MarionFac MedCivello, DanieleRhiem, KerstinStock, StephanieMueller, Dirk...
A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer. Value Health. 2017;20(4):547-555. doi:10.1016/j.jval.2017.01.006Crossref 60. Havrilesky LJ, Broadwater G, Davis DM, et al. Determination of quality of life-...
A new study by a UCLA researcher in collaboration with colleagues at Harvard and University of Texas Southwestern has found that a genomic test widely used to help determine whether women with a common form of breast cancer should undergo radiation is not cost effective. The Oncotype Dx DCIS tes...
Objectives: Genetic mutations in breast cancer susceptibility genes BRCA1/2 are associated with an increased risk of breast/ovarian cancers. Cost-effective preventive measures are available for women who test positive. The objective of this study was to determine at what risk of mutation it is cos...
To evaluate the cost-effectiveness of BRCA testing in women with breast cancer, and cascade testing in family members of BRCA mutation carriers. A cost-effectiveness analysis was conducted using a cohort Markov model from a health-payer perspective. The
This controversy mostly stems from concerns that the harms and cost of routine use of breast MRI outweigh its benefits, suggesting that the test is not cost-effective. Although we acknowledge that the optimal algorithm for breast MRI ... SY Lee,SH Jeong,YN Kim,... - Cancer Sci 被引量: ...
Information about the costs of recurrent breast cancer is potentially important for targeting cost containment strategies and analysing the cost-effectiveness of breast cancer control programmes. We estimated these costs by abstracting health service and
Testing for her2-positive breast cancer: a systematic review and cost- effectiveness analysis. CMAJ 2007;176:1429-34.Dendukuri, N., Khetani, K., Mc... N Dendukuri,K Khetani,M Mcisaac,... - 《Canadian Medical Association Journal》 被引量: 189发表: 2007年 Cost-effectiveness of HER2 te...
Lidg en M; Wilking N; J nsson B;.Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.Acta Oncologica.2008.1018-1028Goodrich K, Kaambwa B, Al-Janabi H. The inclusion of informal care in applied economic evaluation: a review. Value Health. 2012;15(6):975...